Avidan Michael S, Maybrier Hannah R, Abdallah Arbi Ben, Jacobsohn Eric, Vlisides Phillip E, Pryor Kane O, Veselis Robert A, Grocott Hilary P, Emmert Daniel A, Rogers Emma M, Downey Robert J, Yulico Heidi, Noh Gyu-Jeong, Lee Yonghun H, Waszynski Christine M, Arya Virendra K, Pagel Paul S, Hudetz Judith A, Muench Maxwell R, Fritz Bradley A, Waberski Witold, Inouye Sharon K, Mashour George A
Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA.
Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA.
Lancet. 2017 Jul 15;390(10091):267-275. doi: 10.1016/S0140-6736(17)31467-8. Epub 2017 May 30.
Delirium is a common and serious postoperative complication. Subanaesthetic ketamine is often administered intraoperatively for postoperative analgesia, and some evidence suggests that ketamine prevents delirium. The primary purpose of this trial was to assess the effectiveness of ketamine for prevention of postoperative delirium in older adults.
The Prevention of Delirium and Complications Associated with Surgical Treatments [PODCAST] study is a multicentre, international randomised trial that enrolled adults older than 60 years undergoing major cardiac and non-cardiac surgery under general anaesthesia. Using a computer-generated randomisation sequence we randomly assigned patients to one of three groups in blocks of 15 to receive placebo (normal saline), low-dose ketamine (0·5 mg/kg), or high dose ketamine (1·0 mg/kg) after induction of anaesthesia, before surgical incision. Participants, clinicians, and investigators were blinded to group assignment. Delirium was assessed twice daily in the first 3 postoperative days using the Confusion Assessment Method. We did analyses by intention-to-treat and assessed adverse events. This trial is registered with clinicaltrials.gov, number NCT01690988.
Between Feb 6, 2014, and June 26, 2016, 1360 patients were assessed, and 672 were randomly assigned, with 222 in the placebo group, 227 in the 0·5 mg/kg ketamine group, and 223 in the 1·0 mg/kg ketamine group. There was no difference in delirium incidence between patients in the combined ketamine groups and the placebo group (19·45% vs 19·82%, respectively; absolute difference 0·36%, 95% CI -6·07 to 7·38, p=0·92). There were more postoperative hallucinations (p=0·01) and nightmares (p=0·03) with increasing ketamine doses compared with placebo. Adverse events (cardiovascular, renal, infectious, gastrointestinal, and bleeding), whether viewed individually (p value for each >0·40) or collectively (36·9% in placebo, 39·6% in 0·5 mg/kg ketamine, and 40·8% in 1·0 mg/kg ketamine groups, p=0·69), did not differ significantly across groups.
A single subanaesthetic dose of ketamine did not decrease delirium in older adults after major surgery, and might cause harm by inducing negative experiences.
National Institutes of Health and Cancer Center Support.
谵妄是一种常见且严重的术后并发症。亚麻醉剂量的氯胺酮常在术中用于术后镇痛,一些证据表明氯胺酮可预防谵妄。本试验的主要目的是评估氯胺酮预防老年人术后谵妄的有效性。
预防与手术治疗相关的谵妄和并发症[PODCAST]研究是一项多中心、国际随机试验,纳入60岁以上在全身麻醉下接受心脏和非心脏大手术的成年人。使用计算机生成的随机序列,我们将患者随机分为三组,每组15人,在麻醉诱导后、手术切口前分别接受安慰剂(生理盐水)、低剂量氯胺酮(0.5mg/kg)或高剂量氯胺酮(1.0mg/kg)。参与者、临床医生和研究人员对分组情况不知情。术后前3天每天使用谵妄评估方法对谵妄进行两次评估。我们采用意向性分析并评估不良事件。本试验已在clinicaltrials.gov注册,注册号为NCT01690988。
在2014年2月6日至2016年6月26日期间,共评估了1360例患者,672例被随机分组,安慰剂组222例,0.5mg/kg氯胺酮组227例,1.0mg/kg氯胺酮组223例。氯胺酮联合组与安慰剂组患者的谵妄发生率无差异(分别为19.45%和19.82%;绝对差异0.36%,95%CI -6.07至7.38,p=0.92)。与安慰剂相比,氯胺酮剂量增加时术后幻觉(p=0.01)和噩梦(p=0.03)更多。不良事件(心血管、肾脏、感染、胃肠道和出血),无论是单独观察(每组p值>0.40)还是综合观察(安慰剂组36.9%,0.5mg/kg氯胺酮组39.6%,1.0mg/kg氯胺酮组40.8%,p=0.69),各组间均无显著差异。
单次亚麻醉剂量的氯胺酮不能降低老年人大型手术后的谵妄发生率,且可能因引发负面体验而造成伤害。
美国国立卫生研究院和癌症中心支持。